CA2585654C - Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction - Google Patents

Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction Download PDF

Info

Publication number
CA2585654C
CA2585654C CA2585654A CA2585654A CA2585654C CA 2585654 C CA2585654 C CA 2585654C CA 2585654 A CA2585654 A CA 2585654A CA 2585654 A CA2585654 A CA 2585654A CA 2585654 C CA2585654 C CA 2585654C
Authority
CA
Canada
Prior art keywords
carnitine
therapy
sildenafil
acetyl
propionyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2585654A
Other languages
English (en)
French (fr)
Other versions
CA2585654A1 (en
Inventor
Aleardo Koverech
Giorgio Cavallini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2585654A1 publication Critical patent/CA2585654A1/en
Application granted granted Critical
Publication of CA2585654C publication Critical patent/CA2585654C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2585654A 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction Expired - Fee Related CA2585654C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000561A ITRM20040561A1 (it) 2004-11-11 2004-11-11 Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
ITRM2004A000561 2004-11-11
PCT/EP2005/011238 WO2006050794A1 (en) 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
CA2585654A1 CA2585654A1 (en) 2006-05-18
CA2585654C true CA2585654C (en) 2013-04-02

Family

ID=35501123

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2585654A Expired - Fee Related CA2585654C (en) 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction

Country Status (16)

Country Link
US (1) US8003652B2 (enExample)
EP (1) EP1811988B1 (enExample)
JP (1) JP5080263B2 (enExample)
KR (1) KR101455275B1 (enExample)
AT (1) ATE456950T1 (enExample)
CA (1) CA2585654C (enExample)
CY (1) CY1110239T1 (enExample)
DE (1) DE602005019251D1 (enExample)
DK (1) DK1811988T3 (enExample)
ES (1) ES2339265T3 (enExample)
IT (1) ITRM20040561A1 (enExample)
MX (1) MX2007005518A (enExample)
PL (1) PL1811988T3 (enExample)
PT (1) PT1811988E (enExample)
SI (1) SI1811988T1 (enExample)
WO (1) WO2006050794A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222347A (ja) * 2009-02-24 2010-10-07 Daiichi Sankyo Healthcare Co Ltd Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942200D1 (de) 1999-08-13 2010-05-12 Deutsches Krebsforsch Parvovirus NS1 Varianten
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
JP2001233770A (ja) * 2000-02-23 2001-08-28 Dountsuendorufaa Udo 勃起機能不全治療用の経口薬の組合わせ
ITRM20010621A1 (it) * 2001-10-18 2003-04-18 Aldo Fassi Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
ITRM20010708A1 (it) 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITRM20020620A1 (it) 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Also Published As

Publication number Publication date
ES2339265T3 (es) 2010-05-18
PL1811988T3 (pl) 2010-07-30
PT1811988E (pt) 2010-04-08
KR20070085961A (ko) 2007-08-27
JP5080263B2 (ja) 2012-11-21
CA2585654A1 (en) 2006-05-18
EP1811988B1 (en) 2010-02-03
WO2006050794A1 (en) 2006-05-18
JP2008531466A (ja) 2008-08-14
US8003652B2 (en) 2011-08-23
DK1811988T3 (da) 2010-05-17
SI1811988T1 (sl) 2010-10-29
KR101455275B1 (ko) 2014-10-27
EP1811988A1 (en) 2007-08-01
US20080090906A1 (en) 2008-04-17
ITRM20040561A1 (it) 2005-02-11
DE602005019251D1 (de) 2010-03-25
ATE456950T1 (de) 2010-02-15
MX2007005518A (es) 2007-05-18
CY1110239T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
US20050196434A1 (en) Pharmaceutical composition and method for the transdermal delivery of magnesium
ES2626651T3 (es) Composiciones para el tratamiento de la fatiga crónica
US20150250761A1 (en) Compositions and methods for treatment of chronic fatigue
KR20140087037A (ko) 키나제 저해제의 부작용 저감제
EP2925366B1 (en) Pharmaceutical combinations
CN102413687A (zh) 静脉注射布洛芬的施用
US8003652B2 (en) Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction
CA2294095C (en) Synergistically acting compositions for selectively combating tumor tissue
US7956091B2 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
JP7270901B2 (ja) 男性の避妊のための非ホルモン性組成物および方法
BR112021015682A2 (pt) Combinação de silício e magnésio para a prevenção e tratamento contra cãibras musculares
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
JP2022540664A (ja) 石灰化減少に用いる経口ピロリン酸二ナトリウム
CA3243635A1 (en) PHARMACEUTICAL COMPOSITION AND MEDICINE COMPRISING L-TRYPTOPHAN, L-5-HYDROXYTRYPTOPHAN AND A PERIPHERAL DEGRADATION INHIBITOR
JPH01197439A (ja) ある種のｈ↓１およびｈ↓２受容体遮断剤の組合せにより消化管損傷に対して保護された非ステロイド系抗炎症組成物
MXPA06007693A (en) Method of food intake management

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201019